Milrinon Tillomed (Milrinone)

• Milrinone is a phosphodiesterase‑3 inhibitor used in the management of severe cardiac dysfunction.
• Acute decompensated heart failure: improves cardiac output and reduces pulmonary congestion.
• Cardiogenic shock: provides inotropic support to maintain systemic perfusion.
• Post‑cardiac surgery low‑output syndrome: supports hemodynamics during recovery.

• Milrinone selectively inhibits phosphodiesterase‑3 enzymes in cardiac and vascular smooth muscle cells, leading to increased intracellular cyclic AMP. Elevated cAMP enhances calcium influx during systole, producing a positive inotropic effect, while also causing vasodilation by reducing calcium‑mediated vascular tone, thereby decreasing afterload and improving overall cardiac performance.

Milrinone may cause a range of adverse reactions that clinicians monitor during therapy.

Common Side Effects

• Hypotension: reduced blood pressure, especially with rapid infusion.
• Headache: mild to moderate intensity.
• Nausea: occasional gastrointestinal upset.
• Flushing: transient warmth and redness of skin.
• Tachycardia: increased heart rate.
• Arrhythmias: premature beats or mild rhythm changes.

Serious or Rare Side Effects

• Severe arrhythmias: ventricular tachycardia or fibrillation.
• Myocardial ischemia: chest pain due to reduced coronary perfusion.
• Thrombocytopenia: significant drop in platelet count.
• Severe hypotension: dangerous drop in blood pressure requiring intervention.
• Anaphylaxis: rare allergic reaction with respiratory distress.
• Hepatotoxicity: elevated liver enzymes indicating liver injury.

• Milrinone requires careful monitoring and specific precautions before and during administration.
• Blood pressure monitoring: observe for hypotension and adjust infusion rate.
• Cardiac rhythm surveillance: continuous ECG to detect arrhythmias.
• Renal function assessment: dose may need adjustment in renal impairment.
• Avoid in severe aortic stenosis: risk of excessive afterload reduction.
• Hypersensitivity screening: discontinue if allergic reaction occurs.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze.

Milrinone can interact with other medications, altering its efficacy or safety profile.

Major Interactions (Avoid)

• Potent vasodilators (e.g., nitroglycerin): may cause severe hypotension.
• Other inotropes (e.g., dopamine): increased risk of arrhythmias.
• Strong CYP3A4 inhibitors: may raise plasma milrinone levels.

Moderate Interactions (Monitor Closely)

• Beta‑blockers: may blunt inotropic response.
• Loop diuretics: additive hypotensive effect.
• Anticoagulants: monitor for bleeding risk.
• Digoxin: heightened arrhythmia potential.
• ACE inhibitors: monitor blood pressure and renal function.